

VIAL et al.  
Appl. No. 10/521,329  
Atty. Ref.: 2350-102  
Amendment  
November 30, 2010


**AMENDMENTS TO THE CLAIMS:**

Please amend the claims as follows:

Claims 1-52. (Cancelled)


53. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically effective amount of at least one compound

of the having a formula (I)



in which

X represents a group of formula (II)



where Z is a  $-(CH_2)_m$  group, with m = 8 to 21,

n = 0 or 1

and Y = R<sub>3</sub>,

R<sub>1</sub> and R'<sub>1</sub>, identical to or different from one another, being chosen from H, alkyl, OH, O-alkyl, O-aryl, O-CO-alkyl, O-CO-aryl, OSO<sub>2</sub>-alkyl, OSO<sub>2</sub>-aryl, OSO<sub>2</sub>-heterocycle, O-CO-S-alkyl, O-CO-NH-alkyl, O-CO-O-alkyl, O-CO-O-aryl, O-CO-S-aryl, O-CO-NH-aryl, PO(O-alkyl)<sub>2</sub>, PO(O-aryl)<sub>2</sub>, CO-O-CH<sub>2</sub>-aryl, or cycloalkyl,

R<sub>2</sub> and R'<sub>2</sub>, identical to or different from one another, being chosen from H, alkyl, CO-O-CH<sub>2</sub>-aryl, CO-O-alkyl, or cycloalkyl,

R<sub>3</sub> and R'<sub>3</sub>, identical to or different from one another, representing H, alkyl, CO-O-aryl, COO-CH(R)-O-CO-alkyl, PO(O-alkyl)<sub>2</sub>, PO(O-aryl)<sub>2</sub>, PO(ONa)<sub>2</sub>, or CO-O-CH(R)-aryl,

R being H or alkyl,

[[and]] or

R<sub>1</sub> and R<sub>2</sub>, and/or R'<sub>1</sub> and R'<sub>2</sub>, or R<sub>2</sub> and R<sub>3</sub> and/or R'<sub>2</sub> and R'<sub>3</sub>, or R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> and/or R'<sub>1</sub>, R'<sub>2</sub> and R'<sub>3</sub>, together form a nitrogenated mono heterocycle with the nitrogen atom or atoms to which they are respectively attached, or[[ also]],

R<sub>2</sub> and R<sub>3</sub> and/or R'<sub>2</sub> and R'<sub>3</sub> can be the same substituent, double-bonded to the nitrogen, cyclized with, respectively, R<sub>1</sub> or R'<sub>1</sub> in order to form a heterocycle, if appropriate substituted by R<sub>3</sub>, which is chosen from H, alkyl, alkyl substituted by 1, 2 or 3 halogen atoms, aryl, CO-O-alkyl, CO-O-aryl, -CO-OH, -CO-NH<sub>2</sub>, -CN, -CO-NH-alkyl, -CO-NH-aryl, -CO-N-(alkyl)<sub>2</sub>, CO-nitrogenated heterocycle, CO-oxygenated heterocycle, CO-nitrogenated and oxygenated heterocycle, NH<sub>2</sub>, NH-alkyl, N(alkyl)<sub>2</sub>, nitrogenated

heterocycle, oxygenated heterocycle, nitrogenated and oxygenated -heterocycle, -O-alkyl, -O-aryl, -O-CH<sub>2</sub>-aryl, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>NH-alkyl, CH<sub>2</sub>N-dialkyl, CH<sub>2</sub>NH-aryl, CH<sub>2</sub>-nitrogenated heterocycle, CH<sub>2</sub>-oxygenated heterocycle, CH<sub>2</sub>-nitrogenated and oxygenated heterocycle, CH<sub>2</sub>-CO-OH,

or a pharmacologically acceptable salt thereof,

in association with an inert pharmaceutical vehicle,

with the proviso that when R<sub>1</sub> and R<sub>2</sub> form a heterocycle, and R'<sub>1</sub> and R'<sub>2</sub> form the same heterocycle as is formed with R<sub>1</sub> and R<sub>2</sub>, and n=0, and R<sub>3</sub> is hydrogen or alkyl, and R'<sub>3</sub> is hydrogen or alkyl, or

when R<sub>1</sub> and R<sub>3</sub> form a heterocycle, and R'<sub>1</sub> and R'<sub>3</sub> form the same heterocycle as is formed with R<sub>1</sub> and R<sub>3</sub>, and n=0, and R<sub>2</sub> is hydrogen or alkyl, and R'<sub>2</sub> is hydrogen or alkyl,

then m is 12-21.


54. (Previously Presented) The pharmaceutical composition according to claim 53, in a form administrable by oral route, by injectable route, or by rectal route.

Claims 55-57. (Cancelled)

58. (Previously Presented) The pharmaceutical composition of claim 53 for the treatment of malaria.

59. (Previously Presented) A pharmaceutical composition according to claim 53  
wherein the pharmaceutically effective amount is an amount effective to treat malaria.

60. (Currently Amended) A pharmaceutical composition according to claim 53  
wherein said at least one compound [[has]]of the formula (V)



or a pharmacologically acceptable salt thereof.

61. (Previously Presented) A pharmaceutical composition according to claim 60  
wherein in said compound or pharmacologically acceptable salt thereof  $\text{R}_1$ ,  $\text{R}'_1$ ,  $\text{R}_2$ ,  $\text{R}'_2$ ,  
 $\text{R}_3$  and  $\text{R}'_3$  are independent of one another.

62. (Previously Presented) A pharmaceutical composition according to claim 61,  
wherein in said compound or pharmacologically acceptable salt thereof  $\text{R}_1$  and/or  $\text{R}'_1$  do  
not represent a hydrogen atom, whilst  $\text{R}_3$  and/or  $\text{R}'_3$ ,  $\text{R}_2$  and/or  $\text{R}'_2$ , represent a  
hydrogen atom.

63. (Previously Presented) A pharmaceutical composition according to claim 62,  
wherein in said compound or pharmacologically acceptable salt thereof  $\text{R}_1$  and/or  $\text{R}'_1$ ,  
and  $\text{R}_2$  and/or  $\text{R}'_2$  represent a hydrogen atom, whilst  $\text{R}_3$  and/or  $\text{R}'_3$  are different from a  
hydrogen atom.

64. (Previously Presented) A pharmaceutical composition according to claim 60, wherein in said compound or pharmacologically acceptable salt thereof


$R_1$  and  $R_2$ , and/or  $R'_1$  and  $R'_2$ , or

$R_2$  and  $R_3$ , and/or  $R'_2$  and  $R'_3$ , or

$R_1$ ,  $R_2$  and  $R_3$  and/or  $R'_1$ ,  $R'_2$  and  $R'_3$  together form a heterocycle.

65. (Currently Amended) A pharmaceutical composition according to claim 64, wherein in said compound or pharmacologically acceptable salt thereof

$R_1$  and  $R_2$  as well as  $R'_1$  and  $R'_2$  form a heterocycle, of having the general formula (VI)




66. (Currently Amended) A pharmaceutical composition according to claim 65, wherein in said compound or pharmacologically acceptable salt thereof

$R_1$  and  $R_2$ , and/or  $R'_1$  and/or  $R'_2$  represent a  $-(CH_2)_p-$  wherein  $p$  is an integer from 1 to 5, and  $R_3$  and/or  $R'_3$  represents CO-O-alkyl, CO-O-aryl, CO-O-CH<sub>2</sub>-aryl, COO-CH(alkyl)-O-CO-alkyl, PO(O-alkyl)<sub>2</sub>, PO(O-aryl)<sub>2</sub>, alkyl or H represent a hydrogen atom,

VIAL et al.  
Appl. No. 10/521,329  
Atty. Ref.: 2350-102  
Amendment  
November 30, 2010

and R<sub>2</sub> and R<sub>3</sub>, and/or R'<sub>2</sub> and/or R'<sub>3</sub> represent a -(CH<sub>2</sub>)<sub>p</sub>- group, wherein p is an integer from 1 to 5.

67. (Previously Presented) A pharmaceutical composition according to claim 53, wherein in said compound or pharmacologically acceptable salt thereof R<sub>2</sub> and R<sub>3</sub> and/or R'<sub>2</sub> and R'<sub>3</sub> form a same substituent and form together with R<sub>1</sub> or respectively R'<sub>1</sub> a bis-oxadiazole of formula (VIII.)



68. (Previously Presented) A pharmaceutical composition according to any one of claims 60-67, in a form administrable by oral route, by injectable route, or by rectal route.

69. (Previously Presented) A pharmaceutical composition of any one of claims 53, 54 or 60-67, wherein the pharmaceutically effective amount is an amount effective to treat malaria.